Navigation Links
Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series

NEW YORK, Nov. 20 /PRNewswire/ -- Clinical data from a prospective registry presented this week at the 35th Annual Veith Symposium shows DVT treatment with the Trellis(R) Peripheral Infusion System from Bacchus Vascular, Inc. (Santa Clara, CA) successfully breaks up the blood clot in most patients in about 20 minutes.

This technique, called isolated pharmacomechanical thrombolysis, restores blood flow more quickly and safely than current catheter-directed thrombolysis (CDT) techniques. It provides an important adjunct to anti-coagulation alone, the current standard of care, which does not break up the existing clot but simply prevents further clot from forming.

Alan M. Dietzek, MD, Chief of Vascular and Endovascular Surgery at Danbury Hospital, Danbury, Connecticut reported the latest outcomes from the manufacturer's registry of clinical results with the Trellis System at over 360 hospitals in the U.S. and internationally.

In a total of 1,409 limbs treated in 1,304 patients, Grades II and III lysis with restoration of patency in patients with all clot chronicities were achieved in 95% of cases. The vast majority of cases (> 83%) were completed in less than two hours in the single-setting of an interventional suite; and the usage of the Trellis System was typically around 20 minutes. No follow-up monitoring in a costly critical care or intensive care unit was typically needed with the Trellis System, in contrast to this requirement of CDT procedures.

There were no reported bleeding complications related to the Trellis device in acute follow up and the dosage of thrombolytic drugs such as t-PA was reduced by 30% with use of the Trellis device compared to CDT.

"Profound changes in the treatment paradigm for DVT are now underway, as evidenced by the U.S. Surgeon General's recent DVT Call to Action," said Dr. Dietzek. "New clinical guidelines in 2008 from the American College of Chest Physicians and the National Quality Forum support the early removal of blood clots with devices like the Trellis System and clinical data on the use of the device underscore the importance of its growing role."

"The Trellis System multicenter clinical data registry has grown into the world's largest reported prospective endovascular series of DVT patients," stated Scott Cramer, President and CEO of Bacchus Vascular. "We are pleased to see how the increasing clinical utilization of our products is propelling the Company's success."

For more information on the changing treatment paradigm for DVT, visit

About Bacchus Vascular

Bacchus Vascular, Inc. is a privately held medical device company dedicated to the treatment of peripheral vascular disease. Dr. Thomas Fogarty, a noted inventor and cardiovascular surgeon, founded the company with the vision of transforming blood clot removal from peripheral blood vessels into a fast, simple, minimally-invasive catheter-based procedure. Thousands of patients suffering from DVT and other occlusive vascular diseases have been treated worldwide to date using the company's Trellis(R) Peripheral Infusion System and other products. For more information, visit

About VEITHsymposium(TM)

Now in its fourth decade, VEITHsymposium(TM) provides vascular surgeons, interventional radiologists, interventional cardiologists and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The 5-day event features over 400 rapid-fire presentations from world-renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques. Press registration details can be found at VEITHsymposium is sponsored by Cleveland Clinic (Cleveland, OH).

SOURCE Bacchus Vascular, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Trellis(R) Catheter Removes Blood Clots Quickly, Restoring Blood Flow in 771 Deep Vein Thrombosis (DVT) Patients
2. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
3. Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report
4. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
5. Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease
6. ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting
7. Edwards Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
8. Peripheral Arterial Disease to be Treated With New Medicated Stent in Trial at Montefiore
9. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
10. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
11. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  Family Rentals, a ... announced the launch of their newly designed, mobile-responsive ... --> Logo ... --> --> Now, renting essential ... and vacation, just got a whole lot easier ...
(Date:11/24/2015)... --> --> Opportunities ... and PPAR Agonists cholesterol-lowering drugs market ? ... rates? This visiongain report shows you potential ... there. ,  ,Our 199-page report provides 153 tables, charts, ... industry and the future market prospects. Our new study ...
(Date:11/24/2015)... , Nov. 24, 2015  Boston Scientific Corporation (NYSE: ... Oppenheimer 26th Annual Healthcare Conference on December 8, in ... Susie Lisa , vice president, Investor Relations, will participate ... beginning at approximately 8:35 a.m. ET. --> ... in a 30-minute question-and-answer session with the host analyst ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... ... it comes to several aspects of orthopedic care. They have received recognition for ... and general orthopedic care. , Becker's Hospital Review selected hospitals for inclusion ...
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to ... it is critical that the first impression be positive and reflects business values. If ... to buy anything or want to return. They will also share their thoughts about ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... LENR HHT Bolier Reactor System. Brillouin is the developer of renewable energy technologies ... low energy nuclear reactions (“LENR”), announced today that its WET™ and HHT™ Boiler ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... advisory organization, is pleased to welcome Winter-Dent & Company as its newest Partner ... day one to become a client's most trusted advisor regardless of whether that ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... States to support their local poison centers through donations on Tuesday, Dec. 1, ... calls it “a day that inspires people to collaborate in improving their local ...
Breaking Medicine News(10 mins):